Cargando…
Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity
Cardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leuka...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649684/ https://www.ncbi.nlm.nih.gov/pubmed/23690661 http://dx.doi.org/10.1155/2013/370715 |
_version_ | 1782269016915574784 |
---|---|
author | Asrih, Mohamed Mach, François Quercioli, Alessandra Dallegri, Franco Montecucco, Fabrizio |
author_facet | Asrih, Mohamed Mach, François Quercioli, Alessandra Dallegri, Franco Montecucco, Fabrizio |
author_sort | Asrih, Mohamed |
collection | PubMed |
description | Cardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leukaemia inhibitory factor receptor (LIFRβ) subunit and the glycoprotein 130 (gp130, a common signal transducer). Both local and systemic concentrations of CT-1 have been shown to potentially play a critical role in obesity. For instance, CT-1 plasma concentrations have been shown to be increased in metabolic syndrome (a cluster disease including obesity) probably due to adipose tissue overexpression. Interestingly, treatment with exogenous CT-1 has been shown to improve lipid and glucose metabolism in animal models of obesity. These benefits might suggest a potential therapeutic role for CT-1. However, beyond its beneficial properties, CT-1 has been also shown to induce some adverse effects, such as cardiac hypertrophy and adipose tissue inflammation. Although scientific evidence is still needed, CT-1 might be considered as a potential example of damage/danger-associated molecular pattern (DAMP) in obesity-related cardiovascular diseases. In this narrative review, we aimed at discussing and updating evidence from basic research on the pathophysiological and potential therapeutic roles of CT-1 in obesity. |
format | Online Article Text |
id | pubmed-3649684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36496842013-05-20 Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity Asrih, Mohamed Mach, François Quercioli, Alessandra Dallegri, Franco Montecucco, Fabrizio Mediators Inflamm Review Article Cardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leukaemia inhibitory factor receptor (LIFRβ) subunit and the glycoprotein 130 (gp130, a common signal transducer). Both local and systemic concentrations of CT-1 have been shown to potentially play a critical role in obesity. For instance, CT-1 plasma concentrations have been shown to be increased in metabolic syndrome (a cluster disease including obesity) probably due to adipose tissue overexpression. Interestingly, treatment with exogenous CT-1 has been shown to improve lipid and glucose metabolism in animal models of obesity. These benefits might suggest a potential therapeutic role for CT-1. However, beyond its beneficial properties, CT-1 has been also shown to induce some adverse effects, such as cardiac hypertrophy and adipose tissue inflammation. Although scientific evidence is still needed, CT-1 might be considered as a potential example of damage/danger-associated molecular pattern (DAMP) in obesity-related cardiovascular diseases. In this narrative review, we aimed at discussing and updating evidence from basic research on the pathophysiological and potential therapeutic roles of CT-1 in obesity. Hindawi Publishing Corporation 2013 2013-04-10 /pmc/articles/PMC3649684/ /pubmed/23690661 http://dx.doi.org/10.1155/2013/370715 Text en Copyright © 2013 Mohamed Asrih et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Asrih, Mohamed Mach, François Quercioli, Alessandra Dallegri, Franco Montecucco, Fabrizio Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
title | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
title_full | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
title_fullStr | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
title_full_unstemmed | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
title_short | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
title_sort | update on the pathophysiological activities of the cardiac molecule cardiotrophin-1 in obesity |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649684/ https://www.ncbi.nlm.nih.gov/pubmed/23690661 http://dx.doi.org/10.1155/2013/370715 |
work_keys_str_mv | AT asrihmohamed updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity AT machfrancois updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity AT querciolialessandra updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity AT dallegrifranco updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity AT montecuccofabrizio updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity |